|
|
||||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
1 Institute of Medicine, University of Bergen, Bergen, Norway
2 Department of Thoracic Medicine, Haukeland University Hospital, N-5021 Bergen, Norway
3 Centre for Clinical Research, Haukeland University Hospital, N-5021 Bergen, Norway
Correspondence to:
Correspondence to:
MsA Johannessen
Institute of Medicine, University of Bergen, N-5021 Bergen, Norway; ane.johannessen{at}helse-bergen.no
Background: The Global Initiative for Obstructive Lung Disease (GOLD) has defined chronic obstructive pulmonary disease (COPD) as a post-bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) of <0.7. In the first general population based study to apply post-bronchodilator values, the prevalence and predictors of GOLD defined COPD were assessed and the implications of ß2 agonist reversibility testing examined.
Methods: Based on a random population sample, 2235 subjects (77%) aged 2682 years performed spirometric tests before and 15 minutes after inhaling 0.3 mg salbutamol.
Results: The prevalence of GOLD defined COPD was 7.0% (95% confidence interval (CI) 5.9 to 8.0). This estimate was 27% lower than COPD defined without bronchodilatation. One percent of the population had severe or very severe COPD. Compared with women, men had 3.1 (95% CI 2.1 to 4.8) times higher odds for COPD. Subjects with a smoking history of more than 20 pack years had an odds ratio (OR) of 6.2 (95% CI 3.4 to 11.0) for COPD relative to never-smokers, while subjects older than 75 years had an OR of 18.0 (95% CI 9.2 to 35.0) relative to those below 45 years. Subjects with primary education only had an OR of 2.8 (95% CI 1.4 to 5.3) compared with those with university education. Subjects with body mass index (BMI) <20 kg/m2 were more likely than subjects with BMI 2529.9 kg/m2 to have COPD (OR 2.4, 95% CI 1.1 to 5.3). The adjusted proportion of COPD attributable to smoking was 68%.
Conclusions: These results indicate that community programmes on prevention of COPD should focus on anti-smoking, nutritional aspects, and socioeconomic conditions. The effect of ß2 reversibility testing on prevalence estimates of COPD was substantial.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity
Keywords: chronic obstructive pulmonary disease; prevalence; Global Initiative for Obstructive Lung Disease (GOLD); bronchodilatation; epidemiology
This article has been cited by other articles:
![]() |
A. Kainu, A. Lindqvist, S. Sarna, B. Lundback, and A. Sovijarvi FEV1 Response to Bronchodilation in an Adult Urban Population Chest, August 1, 2008; 134(2): 387 - 393. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Bednarek, J Maciejewski, M Wozniak, P Kuca, and J Zielinski Prevalence, severity and underdiagnosis of COPD in the primary care setting Thorax, May 1, 2008; 63(5): 402 - 407. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Viegi, F. Pistelli, D. L. Sherrill, S. Maio, S. Baldacci, and L. Carrozzi Definition, epidemiology and natural history of COPD Eur. Respir. J., November 1, 2007; 30(5): 993 - 1013. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Zhong, C. Wang, W. Yao, P. Chen, J. Kang, S. Huang, B. Chen, C. Wang, D. Ni, Y. Zhou, et al. Prevalence of Chronic Obstructive Pulmonary Disease in China: A Large, Population-based Survey Am. J. Respir. Crit. Care Med., October 15, 2007; 176(8): 753 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Pillai, G. Zhu, A. Gulsvik, D. A. Lomas, and E. K. Silverman SERPINE2 and COPD Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 726 - 726. [Full Text] [PDF] |
||||
![]() |
A. Johannessen, E. R Omenaas, G. E. Eide, P. S Bakke, and A. Gulsvik Feasible and simple exclusion criteria for pulmonary reference populations Thorax, September 1, 2007; 62(9): 792 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Mannino Defining chronic obstructive pulmonary disease... and the elephant in the room Eur. Respir. J., August 1, 2007; 30(2): 189 - 190. [Full Text] [PDF] |
||||
![]() |
P. Shirtcliffe, M. Weatherall, S. Marsh, J. Travers, A. Hansell, A. McNaughton, S. Aldington, H. Muellerova, and R. Beasley COPD prevalence in a random population survey: a matter of definition Eur. Respir. J., August 1, 2007; 30(2): 232 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Dransfield, G. R. Washko, M. G. Foreman, R. S. J. Estepar, J. Reilly, and W. C. Bailey Gender Differences in the Severity of CT Emphysema in COPD Chest, August 1, 2007; 132(2): 464 - 470. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M Mannino, A Sonia Buist, and W. M Vollmer Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax, March 1, 2007; 62(3): 237 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. de Marco, S. Accordini, I. Cerveri, A. Corsico, J. M. Anto, N. Kunzli, C. Janson, J. Sunyer, D. Jarvis, S. Chinn, et al. Incidence of Chronic Obstructive Pulmonary Disease in a Cohort of Young Adults According to the Presence of Chronic Cough and Phlegm Am. J. Respir. Crit. Care Med., January 1, 2007; 175(1): 32 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
D M Mannino Underdiagnosed chronic obstructive pulmonary disease in England: new country, same story. Thorax, December 1, 2006; 61(12): 1032 - 1034. [Full Text] [PDF] |
||||
![]() |
R. J. Halbert, J. L. Natoli, A. Gano, E. Badamgarav, A. S. Buist, and D. M. Mannino Global burden of COPD: systematic review and meta-analysis Eur. Respir. J., September 1, 2006; 28(3): 523 - 532. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Johannessen, S. Lehmann, E. R. Omenaas, G. E. Eide, P. S. Bakke, and A. Gulsvik Post-Bronchodilator Spirometry Reference Values in Adults and Implications for Disease Management Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1316 - 1325. [Abstract] [Full Text] [PDF] |
||||
![]() |
Beta2 agonist reversibility testing in COPD diagnosis DTB, December 1, 2005; 43(12): 89 - 91. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |